AviadoBio
PrivateLast Round
Grant
Mar 31, 2026
Total Funding Raised
$151.89M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AviadoBio is a biotechnology company that develops innovative gene therapies aimed at transforming the lives of individuals affected by severe neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AviadoBio Comparables
Compare AviadoBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Coave Therapeutics | 84% | |
| Capsida Biotherapeutics | 81% | |
| DegenRx B.V. | 79% |
AviadoBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 31, 2026 | ||||
| Strategic | Oct 8, 2024 | ||||
| Series A | Dec 2, 2021 | ||||
| Seed | Apr 1, 2021 | ||||
| Seed | Dec 1, 2020 |
Key People
Founding team and executive leadership
AviadoBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Association for Frontotemporal Degeneration | Grant |
| EQT Life Sciences | Series A |
| SV Health Investors | Seed, Series A |
| New Enterprise Associates | Series A |
| F-Prime Capital | Seed, Series A |
| Advent Life Sciences | Seed, Series A |
| Monograph Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 27, 2026
Combining RNAi platform with TfR1 capsid for CNS gene silencing.
- Apr 27, 2026
Presenting drug candidate data at the ASGCT Annual Meeting.
Recent news
Latest coverage and updates
- attends_eventOct 8, 2026
AviadoBio Ltd plans to present preliminary data from the ongoing Phase 1/2 ASPIRE-FTD trial, including early dose-dependent increases in cerebrospinal fluid progranulin across four ascending doses, at the 15th International Conference on Frontotemporal Dementias.
AviadoBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AviadoBio's valuation, stock price, and market status.
Is AviadoBio a public or private company?
AviadoBio is a private company.
What is the current stock price of AviadoBio?
AviadoBio is a private company, so its shares have no public market price. Caplight tracks AviadoBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AviadoBio worth (valuation)?
Valuation information for AviadoBio is not publicly available.
Can I buy AviadoBio stock?
AviadoBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AviadoBio's last funding round?
AviadoBio's most recent funding round was Grant on March 31, 2026.
Who are the main investors in AviadoBio?
Key investors in AviadoBio include New Enterprise Associates, Monograph Capital.
Will AviadoBio IPO soon?
No public IPO plans have been announced for AviadoBio.
How can I track AviadoBio secondary market activity?
Caplight tracks bids, offers, and trades in AviadoBio's shares on secondary markets.